Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House-Senate Conferees Fight Over Zika Funds As FDA Approves More Assays

This article was originally published in The Gray Sheet

Executive Summary

Emergency funding to battle the summer's mosquito-borne Zika threat is trapped in a military/VA spending bill. Conferees must find a compromise between the House's $622m bid and the Senate's $1.1b offer in the thin stretch of time when both chambers will be session before they adjourn on July 15. In the interim, FDA has authorized more Zika tests.

Advertisement

Related Content

Short-Term US Funding Bill Passes With $1.1bn In Emergency Zika Funds
Zika Assay Reviews Are Testing The Limits Of FDA Capacity, Shuren Says
Hologic/Grifols, Roche Molecular Zika Tests Tapped For Blood-Screening Ramp-Up
Chembio Wins $13.2M US BARDA Contract To Develop POC Zika Tests
Hologic Wins $4.1m To Advance Zika Blood Screen
Manufacturer Doesn’t Expect Zika Blood-Screening Test Shortage
Don't Finalize LDT Guidance, House Appropriators Tell FDA

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT038359

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel